Alnylam Adding Patients to ATTR Trial, Conducting Interim Analysis of RSV Data | GenomeWeb

By Doug Macron

Officials from Alnylam Pharmaceuticals this week provided an update on the company's pipeline, giving details on the timing of key programs and noting that additional patients will be enrolled in an ongoing study of its transthyretin-mediated amyloidosis treatment ALN-TTR01.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.